On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The settlement resolves all patent litigation related to Axsome’s ...

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation Axsome Therapeutics, Inc. Mon, Feb 10, 2025, 7:00 AM 5 min read ...

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.

Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the firm posted ($1.32) earnings per share.

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $125.00. Vikram Purohit’s rating is based on ...